江苏恒瑞医药发布2025年度差异化分红法律意见书，回购股份不参与分红，影响极小
事件概述
江苏恒瑞医药股份有限公司（以下简称“恒瑞医药”或“公司”）于2026年5月发布了关于2025年度利润分配涉及的差异化分红事项的法律意见书。该法律意见书由国浩律师（南京）事务所出具，详细阐述了因公司股份回购产生的差异化分红安排，并确认公司相关分红方案的合法合规性。
核心要点梳理
- 股份回购基本情况：
- 公司于2025年5月14日完成了股份回购，实际回购12,905,144股，占总股本0.20%。回购均价约为46.59元/股，成交总金额约为6.01亿元。
- 部分回购股份已用于2024年员工持股计划，剩余股份继续用于2025年A股员工持股计划。
- 截至法律意见书出具日，公司回购专用证券账户持有6,896,450股股份。
- 回购股份的权利限制：
- 根据相关法规，回购专用账户中的股份不享有利润分配、表决权、认购新股等权利。
- 上述股份不参与2025年度利润分配，导致分红需实施差异化安排。
- 2025年度差异化分红方案：
- 公司2025年度利润分配方案已于2026年4月16日年度股东大会审议通过，拟向全体股东每10股派发现金红利2.00元（含税）。
- 分红基数为分红派息登记日股本扣除回购专用账户持股后的股份数。
- 如总股本发生变化，每股分配比例不变，总金额相应调整。
- 分红计算明细：
- 公司A股总股本为6,379,002,274股，回购专用账户持有6,896,450股，因此实际参与分红的股份为6,372,105,824股。
- 因无送转方案，仅现金分红，流通股份变动比例为0。
- 虚拟分派和实际分派的除权（息）参考价格均为53.43元/股，对除权除息参考价格影响为0.00%，极小（低于1%）。
- 法律合规性结论：
- 律师认为本次差异化分红事项符合《公司法》《证券法》《回购规则》《第7号指引》等法规以及公司章程，不存在损害公司和全体股东利益的情形。
投资者关注要点
- 回购股份不参与分红： 回购专用账户所持股份不参与2025年度利润分配，将导致分红基数减少，但影响极小。
- 影响极小，分红政策稳定： 由于涉及股份占比较小，对每股分红及除权除息价格的影响可以忽略，分红政策稳定。
- 分红方案已获股东大会通过： 分红每10股派2元现金红利，且若股本变动，每股分配比例保持不变，保障了股东利益的稳定性。
- 合规无瑕疵： 律师出具的法律意见书确认分红安排合法合规，为投资者吃下“定心丸”。
对股价的潜在影响
此次差异化分红事项确认了恒瑞医药2025年分红政策的合法性和稳定性，并明确了股份回购对分红及股价的影响极小。对投资者而言，分红政策的稳定与合规性有利于公司形象和市场信心，虽对每股分红影响有限，但传递出公司重视股东回报的积极信号，或对公司长期价值形成正面支撑。
免责声明： 本文内容基于江苏恒瑞医药股份有限公司公开披露的法律意见书，仅供投资者参考，不构成任何投资建议。投资有风险，决策需谨慎。
ENGLISH VERSION
Hengrui Medicine Confirms 2025 Differential Dividend: Repurchased Shares Not Eligible for Dividend, Impact Minimal
Event Overview
Jiangsu Hengrui Medicine Co., Ltd. (“Hengrui Medicine” or “the Company”) released a legal opinion in May 2026 regarding its proposed differential dividend distribution for the year 2025. The legal opinion, prepared by Grandall Law Firm (Nanjing), elaborates on the differentiated dividend plan resulting from the company’s share repurchase program, and affirms the compliance and legality of the proposed dividend scheme.
Key Highlights
- Share Repurchase Details:
- The company completed a share repurchase on May 14, 2025, buying back 12,905,144 shares (0.20% of total share capital) at an average price of RMB 46.59 per share, for a total of approximately RMB 601 million.
- Some repurchased shares were used for the 2024 employee stock ownership plan; remaining shares are allocated to the 2025 A-share employee stock plan.
- As of the date of the legal opinion, the repurchase account holds 6,896,450 shares.
- Restriction on Rights for Repurchased Shares:
- Repurchased shares in the dedicated account do not enjoy dividend rights, voting rights, or subscription rights for new shares, as mandated by regulations.
- Such shares will not participate in the 2025 profit distribution, leading to a differentiated dividend arrangement.
- 2025 Differential Dividend Plan:
- The 2025 profit distribution plan, approved at the annual general meeting on April 16, 2026, proposes a cash dividend of RMB 2.00 (pre-tax) for every 10 shares to all shareholders.
- The dividend is calculated based on total shares outstanding, excluding shares held in the repurchase account, on the dividend record date.
- If total share capital changes, the per-share dividend remains unchanged, with total payout adjusted accordingly.
- Dividend Calculation Details:
- As of the legal opinion date: total A-share capital is 6,379,002,274 shares; repurchase account holds 6,896,450 shares; thus, shares entitled to dividends total 6,372,105,824.
- No bonus shares or transfer of reserves; only cash dividend, so no change in circulating shares.
- Both theoretical and actual ex-dividend reference prices are RMB 53.43 per share; the impact on ex-dividend reference price is 0.00% (less than 1%).
- Legal Compliance Conclusion:
- The lawyers confirm the differentiated dividend arrangement is compliant with the Company Law, Securities Law, repurchase and listing rules, and the Articles of Association, with no harm to the company or shareholders’ interests.
Key Points for Investors
- Repurchased Shares Excluded from Dividend: Shares in the repurchase account will not participate in the 2025 dividend, slightly reducing the dividend base.
- Minimal Impact, Dividend Policy Stable: The affected shares are a tiny proportion of total shares, so the impact on per-share dividend and ex-dividend price is negligible; dividend policy remains stable.
- Dividend Plan Approved: The plan for a cash dividend of RMB 2 per 10 shares has been approved, with the per-share amount fixed even if total shares change—providing stability for shareholder returns.
- Legal Certainty: The opinion provides legal assurance on compliance, supporting investor confidence.
Potential Impact on Share Price
The confirmation of the differentiated dividend arrangement underlines the stability and legality of Hengrui Medicine’s 2025 dividend policy. While the exclusion of repurchased shares from dividends has minimal impact per share, the company’s consistent and compliant dividend policy signals its commitment to shareholder returns, which may support long-term share value and investor confidence.
Disclaimer: This article is based on publicly disclosed legal documents of Jiangsu Hengrui Medicine Co., Ltd. and is for reference only. It does not constitute investment advice. Investments carry risks; investors should exercise caution.
